{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:08:52Z","timestamp":1788754132531,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.vaccine.2021.02.049","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:19:51Z","timestamp":1616113191000},"page":"2201-2213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review"],"prefix":"10.1016","volume":"39","author":[{"given":"Ifechukwu B.","family":"Nwogu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9560-1148","authenticated-orcid":false,"given":"Tessa","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.049_b0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(18)30387-9","article-title":"Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"GBD 2016 Meningitis Collaborators JR","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2021.02.049_b0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1042\/CS20090513","article-title":"Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease","volume":"118","author":"Hill","year":"2010","journal-title":"Clin Sci"},{"key":"10.1016\/j.vaccine.2021.02.049_b0015","unstructured":"WHO. Meningococcal meningitis; n.d. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/meningococcal-meningitis [accessed June 8, 2019]."},{"key":"10.1016\/j.vaccine.2021.02.049_b0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fped.2018.00321","article-title":"Invasive meningococcal disease in the vaccine era","volume":"6","author":"Nadel","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.vaccine.2021.02.049_b0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","article-title":"Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis","volume":"10","author":"Edmond","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.049_b0030","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1099\/mic.0.050518-0","article-title":"Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review","volume":"157","author":"Harrison","year":"2011","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2021.02.049_b0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/20477724.2016.1195072","article-title":"Meningococcal B vaccination: real-world experience and future perspectives","volume":"110","author":"Kuhdari","year":"2016","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2021.02.049_b0040","unstructured":"European Centre for Disease Prevention and Control. Invasive Meningococcal Disease. Annual Epidemiological Report for 2015. Stockholm: ECDC; (2017) n.d. https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2015 [accessed June 17, 2019]."},{"key":"10.1016\/j.vaccine.2021.02.049_b0045","unstructured":"Surveillance of invasive bacterial diseases in Europe; n.d. https:\/\/doi.org\/10.2900\/2884."},{"key":"10.1016\/j.vaccine.2021.02.049_b0050","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0055","doi-asserted-by":"crossref","unstructured":"Meningococcal vaccines: current state and future outlook. Pathol Biol 2015;63:144\u201351. https:\/\/doi.org\/10.1016\/J.PATBIO.2015.04.003.","DOI":"10.1016\/j.patbio.2015.04.003"},{"key":"10.1016\/j.vaccine.2021.02.049_b0060","doi-asserted-by":"crossref","unstructured":"Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect 2014;68:S76\u201382. https:\/\/doi.org\/10.1016\/J.JINF.2013.09.026.","DOI":"10.1016\/j.jinf.2013.09.026"},{"key":"10.1016\/j.vaccine.2021.02.049_b0065","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2217\/fmb.15.91","article-title":"The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects","volume":"10","author":"Mameli","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2021.02.049_b0070","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.02.049_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/archdischild-2015-308928","article-title":"Enter B and W: two new meningococcal vaccine programmes launched","volume":"101","author":"Ladhani","year":"2016","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2021.02.049_b0080","unstructured":"JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK - GOV.UK; n.d. https:\/\/www.gov.uk\/government\/publications\/jcvi-interim-position-statement-on-the-use-of-bexsero-meningococcal-b-vaccine-in-the-uk [accessed August 15, 2019]."},{"key":"10.1016\/j.vaccine.2021.02.049_b0085","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","article-title":"Vaccinating Italian infants with a new multicomponent vaccine (Bexsero\u00ae) against meningococcal B disease: a cost-effectiveness analysis","volume":"12","author":"Gasparini","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.049_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123383","article-title":"Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme","author":"Tirani","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.049_b0095","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jval.2018.09.1421","article-title":"PIN103 - a systematic review: cost-effectiveness of vaccination with new meningococcal serogroup B vaccines","volume":"21","author":"\u0160mit","year":"2018","journal-title":"Value Heal"},{"key":"10.1016\/j.vaccine.2021.02.049_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2021.02.049_b0105","unstructured":"5.1 Introduction to systematic reviews of economic evaluations; n.d."},{"key":"10.1016\/j.vaccine.2021.02.049_b0110","unstructured":"PROSPERO. International prospective register of systematic reviews; n.d. https:\/\/www.crd.york.ac.uk\/PROSPERO\/searchquick.php [accessed July 15, 2019]."},{"key":"10.1016\/j.vaccine.2021.02.049_b0115","doi-asserted-by":"crossref","unstructured":"Drummond M, Sculpher M, Torrance G, O\u2019Brien B. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press; 2005.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"10.1016\/j.vaccine.2021.02.049_b0120","doi-asserted-by":"crossref","DOI":"10.1080\/14737167.2016.1246960","article-title":"How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1\/3)","author":"van Mastrigt","year":"2016","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.vaccine.2021.02.049_b0125","doi-asserted-by":"crossref","DOI":"10.1080\/14737167.2016.1246962","article-title":"How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2\/3)","author":"Thielen","year":"2016","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.vaccine.2021.02.049_b0130","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.1040512","article-title":"Optimal search strategies for detecting health services research studies in MEDLINE","author":"Wilczynski","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2021.02.049_b0135","unstructured":"Canadian Agency for Drugs and Technologies in Health Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9. Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE; 2009."},{"key":"10.1016\/j.vaccine.2021.02.049_b0140","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-013-0471-6","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","author":"Husereau","year":"2013","journal-title":"Eur J Heal Econ"},{"key":"10.1016\/j.vaccine.2021.02.049_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","author":"Husereau","year":"2013","journal-title":"Value Heal"},{"key":"10.1016\/j.vaccine.2021.02.049_b0150","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Chhmewt","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.02.049_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.11.076","article-title":"Modelling the cost-effectiveness of catch-up \u2018MenB\u2019 (Bexsero) vaccination in England","author":"Christensen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0165","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero\u00ae to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.03.020","article-title":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","author":"Lecocq","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0175","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.049_b0180","unstructured":"Hanquet G, Christensen H, Agnew E, Trotter C, Robays J, Dubois C, et al. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study supplement; n.d."},{"key":"10.1016\/j.vaccine.2021.02.049_b0185","doi-asserted-by":"crossref","DOI":"10.1007\/s00038-016-0821-0","article-title":"Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel","author":"Ginsberg","year":"2016","journal-title":"Int J Public Health"},{"key":"10.1016\/j.vaccine.2021.02.049_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","author":"Tu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.amepre.2018.09.020","article-title":"Cost effectiveness of meningococcal serogroup B vaccination in college-aged young adults","volume":"56","author":"Leeds","year":"2019","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2021.02.049_b0200","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2015.1010885","article-title":"Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country","author":"Izquierdo","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2021.02.049_b0205","unstructured":"World Bank Country and Lending Groups \u2013 World Bank Data Help Desk; n.d. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups [accessed July 15, 2019]."},{"key":"10.1016\/j.vaccine.2021.02.049_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.02.049_b0215","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.vaccine.2013.09.055","article-title":"Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing","volume":"32","author":"Azzari","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0220","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2021.02.049_b0225","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e31829cfff2","article-title":"Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial","author":"Snape","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.02.049_b0230","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz251","article-title":"Invasive meningococcal disease in africa\u2019s meningitis belt: more than just meningitis?","volume":"220","author":"Reese","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.049_b0235","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.049_b0240","doi-asserted-by":"crossref","DOI":"10.1177\/0272989X12454578","article-title":"Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force working group-5","author":"Pitman","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vaccine.2021.02.049_b0245","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2015.1137405","article-title":"Economic evaluation of vaccines in Canada: a systematic review","author":"Chit","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2021.02.049_b0250","unstructured":"Di Nardo F, Boccalini S, Calabr\u00f2 GE, Marcellusi A, Ruggeri M, Bonanni P, et al. The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports]. Ig Sanita Pubbl; n.d.;73:453\u201371."},{"key":"10.1016\/j.vaccine.2021.02.049_b0255","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.049_b0260","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0140-6736(13)61925-X","article-title":"Immunisation against meningococcus B","volume":"382","author":"Rappuoli","year":"2013","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:55:04Z","timestamp":1759402504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":52,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0264410X21002292"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}